These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

557 related articles for article (PubMed ID: 33746112)

  • 1. Third-generation cephalosporin resistance in clinical isolates of Enterobacterales collected between 2016-2018 from USA and Europe: genotypic analysis of β-lactamases and comparative in vitro activity of cefepime/enmetazobactam.
    Belley A; Morrissey I; Hawser S; Kothari N; Knechtle P
    J Glob Antimicrob Resist; 2021 Jun; 25():93-101. PubMed ID: 33746112
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Evaluation of the activity of cefepime/enmetazobactam against Enterobacterales bacteria collected in Europe from 2019 to 2021, including third-generation cephalosporin-resistant isolates.
    Morrissey I; Hawser S; Kothari N; Dunkel N; Quevedo J; Belley A; Henriksen AS; Attwood M
    J Glob Antimicrob Resist; 2024 Sep; 38():71-82. PubMed ID: 38723712
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Sigmoid
    Knechtle P; Shapiro S; Morrissey I; De Piano C; Belley A
    Antimicrob Agents Chemother; 2021 Jul; 65(8):e0092621. PubMed ID: 34097479
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Pharmacokinetics-Pharmacodynamics of Enmetazobactam Combined with Cefepime in a Neutropenic Murine Thigh Infection Model.
    Bernhard F; Odedra R; Sordello S; Cardin R; Franzoni S; Charrier C; Belley A; Warn P; Machacek M; Knechtle P
    Antimicrob Agents Chemother; 2020 May; 64(6):. PubMed ID: 32253212
    [TBL] [Abstract][Full Text] [Related]  

  • 5.
    Morrissey I; Magnet S; Hawser S; Shapiro S; Knechtle P
    Antimicrob Agents Chemother; 2019 Jul; 63(7):. PubMed ID: 30988152
    [TBL] [Abstract][Full Text] [Related]  

  • 6.
    Lomovskaya O; Castanheira M; Lindley J; Rubio-Aparicio D; Nelson K; Tsivkovski R; Sun D; Totrov M; Loutit J; Dudley M
    Antimicrob Agents Chemother; 2023 Nov; 67(11):e0044023. PubMed ID: 37800963
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Development of Broth Microdilution MIC and Disk Diffusion Antimicrobial Susceptibility Test Quality Control Ranges for the Combination of Cefepime and the Novel β-Lactamase Inhibitor Enmetazobactam.
    Belley A; Huband MD; Fedler KA; Watters AA; Flamm RK; Shapiro S; Knechtle P
    J Clin Microbiol; 2019 Aug; 57(8):. PubMed ID: 31167844
    [TBL] [Abstract][Full Text] [Related]  

  • 8. In vitro efficacy of imipenem-relebactam and cefepime-AAI101 against a global collection of ESBL-positive and carbapenemase-producing Enterobacteriaceae.
    Tselepis L; Langley GW; Aboklaish AF; Widlake E; Jackson DE; Walsh TR; Schofield CJ; Brem J; Tyrrell JM
    Int J Antimicrob Agents; 2020 Jul; 56(1):105925. PubMed ID: 32084512
    [TBL] [Abstract][Full Text] [Related]  

  • 9.
    Karlowsky JA; Hackel MA; Wise MG; Six DA; Uehara T; Daigle DM; Cusick SM; Pevear DC; Moeck G; Sahm DF
    Antimicrob Agents Chemother; 2023 Jan; 67(1):e0128122. PubMed ID: 36541767
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Assessment of Activity and Resistance Mechanisms to Cefepime in Combination with the Novel β-Lactamase Inhibitors Zidebactam, Taniborbactam, and Enmetazobactam against a Multicenter Collection of Carbapenemase-Producing
    Vázquez-Ucha JC; Lasarte-Monterrubio C; Guijarro-Sánchez P; Oviaño M; Álvarez-Fraga L; Alonso-García I; Arca-Suárez J; Bou G; Beceiro A;
    Antimicrob Agents Chemother; 2022 Feb; 66(2):e0167621. PubMed ID: 34807754
    [TBL] [Abstract][Full Text] [Related]  

  • 11.
    Santerre Henriksen A; Arena F; Attwood M; Canton R; Gatermann S; Naas T; Morrissey I; Longshaw C;
    Microbiol Spectr; 2024 Jun; 12(8):e0418123. PubMed ID: 38904361
    [TBL] [Abstract][Full Text] [Related]  

  • 12.
    Hernández-García M; García-Castillo M; Ruiz-Garbajosa P; Bou G; Siller-Ruiz M; Pitart C; Gracia-Ahufinger I; Mulet X; Pascual Á; Tormo N; Cantón R
    Antimicrob Agents Chemother; 2022 Mar; 66(3):e0216121. PubMed ID: 35007130
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Multicenter surveillance of
    Jean SS; Ko WC; Lu MC; Lee WS; Hsueh PR;
    Expert Rev Anti Infect Ther; 2022 Jun; 20(6):941-953. PubMed ID: 34933656
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Pharmacodynamics of Cefepime Combined with the Novel Extended-Spectrum-β-Lactamase (ESBL) Inhibitor Enmetazobactam for Murine Pneumonia Caused by ESBL-Producing
    Johnson A; McEntee L; Farrington N; Kolamunnage-Dona R; Franzoni S; Vezzelli A; Massimiliano M; Knechtle P; Belley A; Dane A; Drusano G; Das S; Hope W
    Antimicrob Agents Chemother; 2020 May; 64(6):. PubMed ID: 32253209
    [No Abstract]   [Full Text] [Related]  

  • 15. New β-Lactam-β-Lactamase Inhibitor Combinations.
    Yahav D; Giske CG; Grāmatniece A; Abodakpi H; Tam VH; Leibovici L
    Clin Microbiol Rev; 2020 Dec; 34(1):. PubMed ID: 33177185
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Ceftolozane/Tazobactam Activity Against Drug-Resistant
    Pfaller M; Shortridge D; Chen WT; Sader H; Castanheira M
    Infect Drug Resist; 2022; 15():6739-6753. PubMed ID: 36444213
    [TBL] [Abstract][Full Text] [Related]  

  • 17. In vitro activity of the novel β-lactamase inhibitor taniborbactam (VNRX-5133), in combination with cefepime or meropenem, against MDR Gram-negative bacterial isolates from China.
    Wang X; Zhao C; Wang Q; Wang Z; Liang X; Zhang F; Zhang Y; Meng H; Chen H; Li S; Zhou C; Li H; Wang H
    J Antimicrob Chemother; 2020 Jul; 75(7):1850-1858. PubMed ID: 32154866
    [TBL] [Abstract][Full Text] [Related]  

  • 18.
    Karlowsky JA; Hackel MA; Bouchillon SK; Sahm DF
    Antimicrob Agents Chemother; 2020 Nov; 64(12):. PubMed ID: 32928739
    [TBL] [Abstract][Full Text] [Related]  

  • 19. In vitro activity of avibactam (NXL104) in combination with β-lactams against Gram-negative bacteria, including OXA-48 β-lactamase-producing Klebsiella pneumoniae.
    Aktaş Z; Kayacan C; Oncul O
    Int J Antimicrob Agents; 2012 Jan; 39(1):86-9. PubMed ID: 22041508
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Activity of β-lactam/taniborbactam (VNRX-5133) combinations against carbapenem-resistant Gram-negative bacteria.
    Mushtaq S; Vickers A; Doumith M; Ellington MJ; Woodford N; Livermore DM
    J Antimicrob Chemother; 2021 Jan; 76(1):160-170. PubMed ID: 33305800
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 28.